Adnexal Mass Management: Risk Stratification and Management Practice for Best Patient Outcomes

Adnexal Mass Management: Risk Stratification and Management Practice for Best Patient Outcomes

Women's health experts review clinical outcomes and practice management implications of risk assessment methods for ovarian cancer.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Low awareness of women’s risk factors and symptoms for ovarian cancer, compounded by common use of diagnostic laboratory tests that are less sensitive and not specifically approved for assessing the risk of malignant adnexal mass, are the most important reasons that the great majority of women with ovarian cancer are only diagnosed in late stage disease, when prognosis is far worse.

    In this CME activity, join Dr. Burton Brodsky as he reviews best practices in malignancy risk assessment of adnexal mass to improve the detection of ovarian cancer in pre and postmenopausal women in earlier stages, ultimately enhancing their chances at surviving this devastating condition.  Additionally, we will share practical strategies to best inform and empower patients, as well as practice management implications to facilitate patients and clinicians’ access to guideline recommended tools for ovarian cancer risk stratification.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Host:
    Renée Simone Yolanda Allen, MD, MHSc., FACOG
    OB/GYN Hospitalist, Mednax National Medical Group
    3M Physician Documentation Consultant 
    ReachMD Radio Host

    Dr. Allen receives a salary from Mednax LLC, consulting fees from Ferring Pharmaceuticals, and is a speaker for Quest Diagnostics.

    Faculty: 
    Burton S. Brodsky, MD, FACOG
    Director of Minimally Invasive Surgery
    Section Chief Gynecological Services
    Assistant Clinical Professor
    University of Toledo Medical Center
    Toledo, OH

    Dr. Brodsky receives consulting fees from Myriad Genetics and Vermillion, Inc.

    Reviewers/Planners/Authors:

    • Ken Brown has nothing to disclose.
    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
    • Ashley Rosenthal has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply current guidelines to the risk assessment of patients with adnexal mass, and implications for management by the Ob Gyn or Gyn onc
    • Compare the predictive value and regulatory approval status of serum biomarkers and panels of biomarkers currently used to assess the risk of malignancy of suspicious adnexal masses
    • Summarize practice management strategies that will facilitate mutual access for both patients and physicians to complex ovarian cancer risk assessment tools.
  • Target Audience

    This activity is designed to meet the educational needs of Obstetricians, Gynecologists, Gynecologic Oncologists and Primary Care.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from Vermillion, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

NEW FEATURES: